Attorney Docket No.: 4781.1077 10571184 ~ GAU: 1623

Receipt date: 02/17/2011

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Re: Application of: David Morton, et al. Confirmation No.: 9629

Serial No.: 10/571,184

Filed: July 17, 2006 as national phase of International Patent

Application PCT/GB2004/003932, filed September 15, 2004

For: MUCOACTIVE AGENTS FOR TREATING A

PULMONARY DISEASE

TC/A.U.: 1623

Examiner: Eric OLSON

Customer No: 23280

February 17, 2011

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

SIR:

In accordance with Applicants' duty of disclosure under 37 C.F.R. §§ 1.56 and 1.97, Applicant hereby submits this Information Disclosure Statement, including one (1) sheet of Form PTO-1449, for consideration by the Examiner in connection with the above-identified patent application.

Applicants point out that attached as reference A9 is a copy of the European Patent Office's Summons to Oral Proceedings dated December 20, 2010 issued in connection with corresponding European Patent Application No. 04768478.2. Also attached is reference A5 is WO 01/32144 which was cited in the Summons. Applicants note that the following references cited in the Summons are not set forth on the enclosed PTO Form 1449, nor are copies provided herewith because these references were made of record in this application in a previously submitted Information Disclosure Statement.

- Tomkiewicz, R.P., et al., "A comparison of new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog", Pulmonary Pharmacology, 8, pgs. 259-65, 1995
- Tomkiewicz, R.P., et al., "Mucolytic treatment with N-acetylcysteine L-lysinate metered dose inhaler in dogs: airway epithelial function changes", Eur. Respir J., 7, pgs. 81-87, 1994

Receipt date: 02/17/2011

- WO 00/33811 A2 (Vectura Ltd. [GB]; Ganderton David [GB]; Morton David Alexander Vodden) 15 June 2000 (2000-06-15)
- Lucas, Paul, et al., "Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive", Pharmaceutical Research, Vol. 16, No. 10, pgs. 1643-47 1999

In addition, a copy of the Japanese Office Action dated December 14, 2010 is submitted as reference A10. A copy of references A5 (WO 01/32144) and A6 WO 01/34232 which are listed under the heading "Record of Prior Art Search" in the Japanese Office Action, are enclosed herewith. It should be noted that neither WO 01/32144 and WO 01/34232 were cited by the Japanese Patent Office for purposes of rejecting the application. Applicants note that copies of the following references cited in the Japanese Office Action are not set forth on the enclosed PTO Form 1449 because these references were made of record in this application in a previously submitted Information Disclosure Statement.

- PCT International Publication No. WO 01/15672
- PCT International Publication No. WO 03/068188
- PCT International Publication No. WO 03/068187
- PCT International Publication No. WO 03/068254
- PCT International Publication No. WO 99/06025
- PCT International Publication No. WO 97/06783

Additionally, WO 97/06783 is not set forth on the PTO Form 1449 because corresponding U.S. Patent No. 5,690,910 was previously submitted in an Information Disclosure Statement.

The present Information Disclosure Statement is filed under 37 C.F.R. § 1.97(d) and (e)(1), before the payment of the issue fee and each item of information contained in the Information Disclosure Statement was first cited in the Japanese Office Action dated December 14, 2010 or in the European Summons dated December 20, 2010 (i.e. a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement). Accordingly, the present Information Disclosure Statement is timely. Applicants enclose the requisite fee due under 37 C.F.R. § 1.17(p), in connection with the filing of this Information Disclosure Statement. If it is determined that any additional fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

Attorney Docket No.: 4781.1077 10571184 - GAU: 1623

Receipt date: 02/17/2011

Applicants respectfully request that the references cited in the accompanying PTO 1449 form be considered and made of record. Applicants respectfully submit that the pending claims are patentable over all of the references made of record at this time.

Respectfully submitted, DAVIDSON, DAVIDSON & KAPPEL, LLC

By: /Leslye B, Davidson/ Leslye B. Davidson, Reg. No. 38,854

DAVIDSON, DAVIDSON & KAPPEL, LLC 485 Seventh Avenue, 14th Floor New York, NY 10018 (212) 736-1940

FORM PTO- (REV. 7-80)	1449	U.S. DEPARTMENT OF COMME PATENT AND TRADEMARK OF				ATTY DOCKET NO.			APPLICATION NO		
						4781.1077			10/571,184		
	CANT		APPLICA		-6 -1						
						David	Morton	, et al.			_
	(Use several sheet		FILING DATE				GROUP				
		-	July 17, 2006			1623					
			U.S. PA	TENT D	OCUM	ENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	DATE N		E		CLASS	SUB- CLASS	FILING DATE IF APPROPRIA	
	A01										
	A02								<u> </u>		
	A03										
	A04										
			FOREIGN	PATEN	TDOCL	MENT	s				
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUB- CLASS		TRANSLATION		
					.,,,,	05.00	CENSO	YES N			
/ESO/	A05	WO 01/32144	2001-05-10	V	10						Г
/ESO/	A06	WO 01/34232	2001-05-17	V	wo						Г
	A07										T
	A08										T
											_
		OTHER REFERE	NCES (Includia	ng Auth	or, Title,	Date, I	Pertiner	nt Pages,	Etc.)		
/ESO/	A09	European Patent Office's Summons to Oral Proceedings dated December 20, 2010 issued in connection with correspon European Patent Application No. 04768478.2								orrespondin	g
/ESO/	A10	Japanese Office Action dated December 14, 2010									
	A11				-						
	A12										
	A13										
	A14										_
	A15										
	A16										
EXAMINER	1	/Eric Olson/			ATE CO	ONSIDERED 02/22/2011					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.